Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma.

Lazo de la Vega L, Samaha MC, Hu K, Bick NR, Siddiqui J, Hovelson DH, Liu CJ, Carter CS, Cho KR, Sciallis AP, Tomlins SA.

Mol Cancer Res. 2019 Jan 4. pii: molcanres.1178.2018. doi: 10.1158/1541-7786.MCR-18-1178. [Epub ahead of print]

PMID:
30610106
2.

Somatic mutations in adrenocortical carcinoma with hyperaldosteronism.

Mouat IC, Omata K, McDaniel AS, Hattangady N, Talapatra D, Cani AK, Hovelson DH, Tomlins SA, Rainey W, Hammer G, Giordano TJ, Else T.

Endocr Relat Cancer. 2018 Nov 1. pii: ERC-18-0385.R2. doi: 10.1530/ERC-18-0385. [Epub ahead of print]

PMID:
30475217
3.

Transcriptomic heterogeneity in multifocal prostate cancer.

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, Shariat SF, Tomlins SA, Palapattu GS.

JCI Insight. 2018 Nov 2;3(21). pii: 123468. doi: 10.1172/jci.insight.123468. [Epub ahead of print]

4.

Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.

Hovelson DH, Udager AM, McDaniel AS, Grivas P, Palmbos P, Tamura S, Lazo de la Vega L, Palapattu G, Veeneman B, El-Sawy L, Sadis SE, Morgan TM, Montgomery JS, Weizer AZ, Day KC, Neamati N, Liebert M, Keller ET, Day ML, Mehra R, Tomlins SA.

Eur Urol. 2018 Dec;74(6):741-753. doi: 10.1016/j.eururo.2018.06.047. Epub 2018 Jul 20.

PMID:
30033047
5.

Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma.

Udager AM, McDaniel AS, Hovelson DH, Fields K, Salami SS, Kaffenberger SD, Spratt DE, Montgomery JS, Weizer AZ, Reichert ZR, Alva AS, Chinnaiyan AM, Tomlins SA, Mehra R.

Eur Urol. 2018 Oct;74(4):529-531. doi: 10.1016/j.eururo.2018.06.019. Epub 2018 Jul 3. No abstract available.

PMID:
29980330
6.

Aldosterone-Producing Cell Clusters Frequently Harbor Somatic Mutations and Accumulate With Age in Normal Adrenals.

Omata K, Anand SK, Hovelson DH, Liu CJ, Yamazaki Y, Nakamura Y, Ito S, Satoh F, Sasano H, Rainey WE, Tomlins SA.

J Endocr Soc. 2017 May 12;1(7):787-799. doi: 10.1210/js.2017-00134. eCollection 2017 Jul 1.

7.

Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms.

Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, Yazdani M, Blevins AR, Sero V, Tokudome N, Thomas DG, Gersch C, Schott AF, Wu YM, Lonigro R, Robinson DR, Chinnaiyan AM, Bischoff FZ, Johnson MD, Park BH, Hayes DF, Rae JM, Tomlins SA.

Cancer Res. 2018 Feb 15;78(4):1110-1122. doi: 10.1158/0008-5472.CAN-17-2686. Epub 2017 Dec 12.

PMID:
29233927
8.

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.

Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA.

Oncotarget. 2017 Sep 22;8(52):89848-89866. doi: 10.18632/oncotarget.21163. eCollection 2017 Oct 27.

9.

Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications.

Lazo de la Vega L, McHugh JB, Cani AK, Kunder K, Walocko FM, Liu CJ, Hovelson DH, Robinson D, Chinnaiyan AM, Tomlins SA, Harms PW.

Mol Cancer Res. 2017 Nov;15(11):1551-1557. doi: 10.1158/1541-7786.MCR-17-0135. Epub 2017 Aug 3.

10.

Molecular Profiling of Multiple Primary Merkel Cell Carcinoma to Distinguish Genetically Distinct Tumors From Clonally Related Metastases.

Harms KL, Lazo de la Vega L, Hovelson DH, Rahrig S, Cani AK, Liu CJ, Fullen DR, Wang M, Andea AA, Bichakjian CK, Johnson TM, Tomlins SA, Harms PW.

JAMA Dermatol. 2017 Jun 1;153(6):505-512. doi: 10.1001/jamadermatol.2017.0507.

11.

Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer.

Palapattu GS, Salami SS, Cani AK, Hovelson DH, Lazo de la Vega L, Vandenberg KR, Bratley JV, Liu CJ, Kunju LP, Montgomery JS, Morgan TM, Natarajan S, Huang J, Tomlins SA, Marks LS.

Clin Cancer Res. 2017 Feb 15;23(4):985-991. doi: 10.1158/1078-0432.CCR-16-1454. Epub 2016 Oct 7.

12.

Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.

Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC.

Oncotarget. 2017 Jan 31;8(5):7989-7998. doi: 10.18632/oncotarget.14008.

13.

Characterization of ADME gene variation in 21 populations by exome sequencing.

Hovelson DH, Xue Z, Zawistowski M, Ehm MG, Harris EC, Stocker SL, Gross AS, Jang IJ, Ieiri I, Lee JE, Cardon LR, Chissoe SL, Abecasis G, Nelson MR.

Pharmacogenet Genomics. 2017 Mar;27(3):89-100. doi: 10.1097/FPC.0000000000000260.

14.

Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.

Smith SC, Trpkov K, Chen YB, Mehra R, Sirohi D, Ohe C, Cani AK, Hovelson DH, Omata K, McHugh JB, Jochum W, Colecchia M, Amin M, Divatia MK, Hes O, Menon S, Werneck da Cunha I, Tripodi S, Brimo F, Gill AJ, Osunkoya AO, Magi-Galluzzi C, Sibony M, Williamson SR, Nesi G, Picken MM, Maclean F, Agaimy A, Cheng L, Epstein JI, Reuter VE, Tickoo SK, Tomlins SA, Amin MB.

Am J Surg Pathol. 2016 Nov;40(11):1457-1472.

15.

The Role of Next-Generation Sequencing in Castration-Resistant Prostate Cancer Treatment.

Hovelson DH, Tomlins SA.

Cancer J. 2016 Sep/Oct;22(5):357-361. Review.

16.

Targeted next-generation sequencing of CIC-DUX4 soft tissue sarcomas demonstrates low mutational burden and recurrent chromosome 1p loss.

Lazo de la Vega L, Hovelson DH, Cani AK, Liu CJ, McHugh JB, Lucas DR, Thomas DG, Patel RM, Tomlins SA.

Hum Pathol. 2016 Dec;58:161-170. doi: 10.1016/j.humpath.2016.09.004. Epub 2016 Sep 21.

17.

Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.

Cani AK, Soliman M, Hovelson DH, Liu CJ, McDaniel AS, Haller MJ, Bratley JV, Rahrig SE, Li Q, Briceño CA, Tomlins SA, Rao RC.

Mod Pathol. 2016 Jul;29(7):685-97. doi: 10.1038/modpathol.2016.79. Epub 2016 Apr 22.

18.

Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations.

Harms PW, Hovelson DH, Cani AK, Omata K, Haller MJ, Wang ML, Arps D, Patel RM, Fullen DR, Wang M, Siddiqui J, Andea A, Tomlins SA.

Hum Pathol. 2016 May;51:25-31. doi: 10.1016/j.humpath.2015.12.015. Epub 2016 Jan 7.

PMID:
27067779
19.

Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.

Tillman BN, Yanik M, Birkeland AC, Liu CJ, Hovelson DH, Cani AK, Palanisamy N, Carskadon S, Carey TE, Bradford CR, Tomlins SA, McHugh JB, Spector ME, Brenner JCh.

Head Neck. 2016 Apr;38 Suppl 1:E1646-52. doi: 10.1002/hed.24292. Epub 2016 Feb 5.

20.

Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.

Harms PW, Collie AM, Hovelson DH, Cani AK, Verhaegen ME, Patel RM, Fullen DR, Omata K, Dlugosz AA, Tomlins SA, Billings SD.

Mod Pathol. 2016 Mar;29(3):240-8. doi: 10.1038/modpathol.2015.154. Epub 2016 Jan 8.

21.

Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy.

McDaniel AS, Hovelson DH, Cani AK, Liu CJ, Zhai Y, Zhang Y, Weizer AZ, Mehra R, Feng FY, Alva AS, Morgan TM, Montgomery JS, Siddiqui J, Sadis S, Bandla S, Williams PD, Cho KR, Rhodes DR, Tomlins SA.

Cancer Res. 2015 Dec 15;75(24):5219-27. doi: 10.1158/0008-5472.CAN-15-1004.

22.

Intra-tumor genetic heterogeneity in rectal cancer.

Hardiman KM, Ulintz PJ, Kuick RD, Hovelson DH, Gates CM, Bhasi A, Rodrigues Grant A, Liu J, Cani AK, Greenson JK, Tomlins SA, Fearon ER.

Lab Invest. 2016 Jan;96(1):4-15. doi: 10.1038/labinvest.2015.131. Epub 2015 Nov 16.

23.

Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.

Kadakia KC, Tomlins SA, Sanghvi SK, Cani AK, Omata K, Hovelson DH, Liu CJ, Cooney KA.

J Hematol Oncol. 2015 Oct 6;8:109. doi: 10.1186/s13045-015-0204-7.

24.

Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands.

Nishimoto K, Tomlins SA, Kuick R, Cani AK, Giordano TJ, Hovelson DH, Liu CJ, Sanjanwala AR, Edwards MA, Gomez-Sanchez CE, Nanba K, Rainey WE.

Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):E4591-9. doi: 10.1073/pnas.1505529112. Epub 2015 Aug 3.

25.

Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.

McDaniel AS, Stall JN, Hovelson DH, Cani AK, Liu CJ, Tomlins SA, Cho KR.

JAMA Oncol. 2015 Nov;1(8):1128-32. doi: 10.1001/jamaoncol.2015.1618.

26.

Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan AM.

Eur Urol. 2016 Jul;70(1):45-53. doi: 10.1016/j.eururo.2015.04.039. Epub 2015 May 16.

27.

Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.

Hovelson DH, McDaniel AS, Cani AK, Johnson B, Rhodes K, Williams PD, Bandla S, Bien G, Choppa P, Hyland F, Gottimukkala R, Liu G, Manivannan M, Schageman J, Ballesteros-Villagrana E, Grasso CS, Quist MJ, Yadati V, Amin A, Siddiqui J, Betz BL, Knudsen KE, Cooney KA, Feng FY, Roh MH, Nelson PS, Liu CJ, Beer DG, Wyngaard P, Chinnaiyan AM, Sadis S, Rhodes DR, Tomlins SA.

Neoplasia. 2015 Apr;17(4):385-99. doi: 10.1016/j.neo.2015.03.004.

28.

Integrative molecular profiling of routine clinical prostate cancer specimens.

Grasso CS, Cani AK, Hovelson DH, Quist MJ, Douville NJ, Yadati V, Amin AM, Nelson PS, Betz BL, Liu CJ, Knudsen KE, Cooney KA, Feng FY, McDaniel AS, Tomlins SA.

Ann Oncol. 2015 Jun;26(6):1110-8. doi: 10.1093/annonc/mdv134. Epub 2015 Mar 3.

29.

Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.

Cani AK, Hovelson DH, McDaniel AS, Sadis S, Haller MJ, Yadati V, Amin AM, Bratley J, Bandla S, Williams PD, Rhodes K, Liu CJ, Quist MJ, Rhodes DR, Grasso CS, Kleer CG, Tomlins SA.

Mol Cancer Res. 2015 Apr;13(4):613-9. doi: 10.1158/1541-7786.MCR-14-0578. Epub 2015 Jan 15.

30.

Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma.

Warrick JI, Hovelson DH, Amin A, Liu CJ, Cani AK, McDaniel AS, Yadati V, Quist MJ, Weizer AZ, Brenner JC, Feng FY, Mehra R, Grasso CS, Tomlins SA.

Virchows Arch. 2015 Mar;466(3):297-311. doi: 10.1007/s00428-014-1699-y. Epub 2014 Dec 11.

31.

No large-effect low-frequency coding variation found for myocardial infarction.

Holmen OL, Zhang H, Zhou W, Schmidt E, Hovelson DH, Langhammer A, Løchen ML, Ganesh SK, Mathiesen EB, Vatten L, Platou C, Wilsgaard T, Chen J, Skorpen F, Dalen H, Boehnke M, Abecasis GR, Njølstad I, Hveem K, Willer CJ.

Hum Mol Genet. 2014 Sep 1;23(17):4721-8. doi: 10.1093/hmg/ddu175. Epub 2014 Apr 12.

32.

Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk.

Holmen OL, Zhang H, Fan Y, Hovelson DH, Schmidt EM, Zhou W, Guo Y, Zhang J, Langhammer A, Løchen ML, Ganesh SK, Vatten L, Skorpen F, Dalen H, Zhang J, Pennathur S, Chen J, Platou C, Mathiesen EB, Wilsgaard T, Njølstad I, Boehnke M, Chen YE, Abecasis GR, Hveem K, Willer CJ.

Nat Genet. 2014 Apr;46(4):345-51. doi: 10.1038/ng.2926. Epub 2014 Mar 16.

Supplemental Content

Loading ...
Support Center